• 45-1 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-466-5530

Aptamers for SARS-CoV-2

Creative Biolabs has successfully developed Aptamers for SARS-CoV-2 with high affinity. Creative Biolabs actively invests in aptamer development to assist researchers to better understand the characteristics of SARS-CoV-2 and drug development.

Explore the collections of SARS-CoV-2 aptamers

The alternative pathway is a branch of the complement network, which is generally recognized as an important conservator to recognize and eliminate the pathogens through direct killing or stimulation of phagocytosis. Besides the immunoregulatory functions, complement system has been elaborated on the pathogenic role of ischemic injury, inflammatory, and autoimmune diseases.

The alternative pathway is an independent defense mechanism of the immune response, and it plays an indispensable role in the defense against infections, especially in the early stage while specific antibodies have not been produced. In the physical circumstances, this pathway is slowly activated by spontaneous hydrolysis of the internal C3 thioester bond. When the foreign excitant (e.g. various proteins, lipids and carbohydrate structures on microorganisms) contact with C3, alternative pathway is amplified quickly.

Components of Alternative Pathway

Compared with classical pathway and lectin pathway, the common components are C3, C5-C9, while the unique components are:

  1. Factor B
  2. Factor D
  3. Factor P (properdin)

Aided by factor B/factor D-targeted transgenic mice, investigators demonstrated that all of them are required for efficient alternative pathway activation by zymosan.

Activation Mechanisms of Alternative Pathway

In contrast to classical and lectin pathway, the alternative pathway is capable of autoactivation because of a process termed “tickover” of C3. A conformationally altered C3, designated C3(H2O) is the production of tickover. Normally, the rate of spontaneously tickover is extremely low to 1% of total C3. C3(H2O) has the capability to bind factor B, which can be cleaved into Ba and Bb followed by the constitutively active serum protease factor D. Bb remains bound to C3(H2O) to form C3(H2O)Bb, the alternative pathway C3-convertase, which has the serine protease activity to cleave multiple C3 into C3b to generate more C3 convertase in a powerful amplification loop, resulting in the full activation of the complement system. C3bBb is unstable until it binds properdin to form the complex C3bBbP, a stable form which can bind an additional C3b to form C5-convertase, (C3b)2BbP. Then the alternative pathway follows the same path as the classical or lectin pathway. C5-convertase cleaves C5 into C5a and C5b. C5b recruits C6, C7, C8 C9 to form membrane attack complex (MAC) inducing cell lysis.

The illustration of activation mechanisms of the alternative pathway.

Fig 1. The illustration of activation mechanisms of the alternative pathway.

The Regulation of Alternative Pathway

Because of the spontaneous activating capabilities, the C3 convertase amplification loop in alternative pathway requires rigorous control to prevent inadvertent inflammation and damage.
  1. Complement Factor I (CFI): it is a plasma protease, which prevents the reassembles of the C3 convertase by proteolytic inactivation of C3b to iC3b (inactive C3b).
  2. Complement Factor H (CFH): it plays important regulatory functions via several ways. It inhibits the formation of the C3 convertase by competing with factor B for binding to C3b, and accelerates the dissociation of the C3bBb convertase complex. Moreover, it acts as a cofactor in the cleavage of C3b to iC3b.
  3. Complement Factor H-Related protein (CFHR): it plays control action by competing with CFH for binding to C3b. CFHR5 is demonstrated as a cofactor for CFI.

The regulation of alternative pathway.

Fig 2. The regulation of alternative pathway. (De, et al. 2015)

Creative Biolabs provides a full range of therapeutic antibodies, inhibitors, soluble complement regulators, as well as customized services based on the alternative pathway. If you are interested, please feel free to contact us for more details.

Reference
1. De Vriese A S, et al. (2015). Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. Journal of the American Society of Nephrology. 26(12), 2917-2929.

For lab research use only.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact us

USA

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • Tel: 1-631-466-5530
  • Fax: 1-631-207-8356
  • Email:

Europe

  • Heidenkampsweg 58, 20097 Hamburg, Germany
  • Tel: 44-207-097-1828
  • Email:
Complement System
Copyright © 2007 - 2020 Creative Biolabs. All Rights Reserved.